Expression of the chemokine CCL24 and its receptor CCR3 in the sera and livers of patients with non-alcoholic fatty liver disease

Maor Yaakon1, Haberman Dan2, Segal-Salito Michal2, Katav Avi1, Hashmueli Sharon1, Jacob George2, Mor Adi3

Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, Israel1, Heart Center, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew university, Jerusalem, Israel1, ChemomAb Ltd, Tel Aviv Israel2

INTRODUCTION
• Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease.
• Inflammation and fibrosis are the key pathological processes involved in the progression of NAFLD to Non-alcoholic steatohepatitis (NASH).
• Chemokines play an important role in inducing inflammation and fibrosis and were found to play a key role in NASH progression.
• CCL24 (Eotaxin-2) was recently found to be involved in the progression of inflammatory and fibrotic diseases.
• ChemomAb is developing Anti-CCL24 monoclonal antibody for the treatment of NASH.

AIM
To study the levels of circulating CCL24 and its receptor CCR3 in NAFLD patients’ serum samples and liver biopsies and the association with disease stage.

METHOD
• Serum samples from NAFLD patients in different disease stages were analyzed for CCL24 levels using commercial ELISA kit.
• CCR3 expression in peripheral blood mononuclear cells was tested by flow cytometry.
• Immunohistochemistry staining was performed to evaluate CCL24 and CCR3 expression in liver biopsies.
• Fib4 score was used to divide the NAFLD population to subgroups according to disease severity.

CONCLUSIONS
• We present for the first time, evidence that the chemokine CCL24 and its cognate receptor, CCR3, are significantly increased in NAFLD patients both in the circulation and in the liver. Furthermore, CCL24 expression correlates with disease severity.
• These results may indicate a potential involvement of CCL24-CCR3 axis in the pathogenesis of NASH, thus suggesting that CCL24 may serve as a potential prognostic tool and a therapeutic target for the treatment of patients with NASH.

REFERENCES
Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview; Bellando Randone S et al; 2018; Journal of Scleroderma and Related Disorders.
CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis; Jin L et al; 2016; Oncotarget.
Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis; Ablin JN et al; 2010; Clinical and Experimental Immunology.